The company's financial flexibility is severely constrained by a debt-to-equity ratio of 7.90 and an equity base that has contracted to $2.8 million as of 2024Q2.
| Total Current Assets | 9.54M | 31.19M | 13.75M | 5.33M | 1.08M | 581.7K |
| Cash & Short-Term Investments | 1.93M | 9.02M | 5.39M | 2.83M | 1.08M | 337.6K |
| Cash Only | 1.93M | 767.92K | 5.39M | 2.53M | 1.08M | 337.6K |
| Short-Term Investments | 0 | 8.25M | 0 | 306.03K | 0 | 0 |
| Accounts Receivable | 2.74M | 19.92M | 1.48M | 1.69M | 0 | 0 |
| Days Sales Outstanding | 88.34 | 21.8 | 96.17 | 682.08 | - | - |
| Inventory | 4.84M | 2.24M | 6.28M | 465.75K | 0 | 0 |
| Days Inventory Outstanding | 184.05 | 3.72 | 444.83 | 162.16 | - | - |
| Other Current Assets | 0 | 0 | 0 | 0 | 0 | 244.09K |
| Total Non-Current Assets | 21.84M | 173.52M | 21.04M | 18.72M | 4.61M | 138.01M |
| Property, Plant & Equipment | 1.63M | 3.45M | 1.62M | 1.19M | 8.92K | 0 |
| Fixed Asset Turnover | 4.86x | 96.81x | 3.48x | 0.76x | - | - |
| Goodwill | 281.03K | 0 | 262.53K | 251.44K | 0 | 0 |
| Intangible Assets | 9.06M | 75.26M | 8.98M | 8.52M | 4.6M | 0 |
| Long-Term Investments | 41.29M | 94.81M | 10.15M | 8.76M | 138.01M | 138.01M |
| Other Non-Current Assets | 25.45K | 0 | 36.02K | 0 | -138.01M | 0 |
| Total Assets | 31.38M | 204.71M | 34.79M | 24.05M | 5.69M | 138.59M |
| Asset Turnover | 0.25x | 1.63x | 0.16x | 0.04x | - | - |
| Asset Growth % | 166.44% | 488.47% | 44.64% | 322.57% | -95.89% | - |
| Total Current Liabilities | 6.46M | 236.05M | 8.15M | 12.6M | 4.09M | 861.85K |
| Accounts Payable | 1.03M | 6.49M | 873.53K | 2.34M | 164.13K | 0 |
| Days Payables Outstanding | 35.31 | 10.79 | 61.88 | 814.39 | - | - |
| Short-Term Debt | 2.37M | 227.27M | 2.56M | 2.55M | 125K | 125K |
| Deferred Revenue (Current) | 0 | 1.26K | 0 | 0 | 0 | 0 |
| Other Current Liabilities | 486.69K | 2.05M | 789.87K | 1.65M | 2.74M | 736.85K |
| Current Ratio | 1.48x | 0.13x | 1.69x | 0.42x | 0.27x | 0.67x |
| Quick Ratio | 0.73x | 0.12x | 0.92x | 0.39x | 0.27x | 0.67x |
| Cash Conversion Cycle | 237.07 | 14.72 | 479.12 | 29.85 | - | - |
| Total Non-Current Liabilities | 22.13M | 51.53M | 19.82M | 1.35M | 2.2M | 3.64M |
| Long-Term Debt | 19.37M | 19.61M | 11.7M | 99.05K | 0 | 0 |
| Capital Lease Obligations | 910.68K | 0 | 248.53K | 0 | 0 | 0 |
| Deferred Tax Liabilities | 1.02M | 15.77M | 72.1K | 1.07M | 0 | 0 |
| Other Non-Current Liabilities | 2.27M | 16.15M | 7.8M | 175.31K | 2.2M | 3.64M |
| Total Liabilities | 28.58M | 287.58M | 27.97M | 13.95M | 4.09M | 4.51M |
| Total Debt | 22.09M | 246.88M | 14.68M | 2.65M | 125K | 125K |
| Net Debt | 20.16M | 246.11M | 9.29M | 117.62K | -956.81K | -212.6K |
| Debt / Equity | 7.90x | - | 2.15x | 0.26x | 0.08x | 0.00x |
| Debt / EBITDA | -2.78x | 20.97x | - | - | - | 0.65x |
| Net Debt / EBITDA | -2.54x | 20.90x | - | - | - | -1.10x |
| Interest Coverage | -2.94x | -0.25x | -7.76x | -41.58x | -805.94x | - |
| Total Equity | 2.8M | -82.87M | 6.82M | 10.11M | 1.6M | 134.08M |
| Equity Growth % | -169.4% | -1315.91% | -32.56% | 529.91% | -98.8% | - |
| Book Value per Share | 1.08 | -192.34 | 2.66 | 4.40 | 0.64 | 115.79 |
| Total Shareholders' Equity | 2.8M | -65.97M | 6.82M | 10.11M | 1.6M | 134.08M |
| Common Stock | 401.27K | 1.09M | 385.64K | 375.64K | 638.3K | 129.08M |
| Retained Earnings | -70.28M | -110.32M | -65.94M | -58.62M | -6.83M | -828.08K |
| Treasury Stock | -305K | -422.15K | -305K | 0 | 0 | - |
| Accumulated OCI | 786.33K | 3.93M | 125.71K | 18.11K | 0 | 0 |
| Minority Interest | 0 | -16.9M | 0 | 0 | 0 | 0 |
Critical liquidity and dilution
As reported in recent financial filings, Moolec's equity base has contracted significantly from $23.9 million in 2022Q1 to just $2.8 million by 2024Q2, signaling a deteriorating financial position driven by persistent net losses and the ongoing consumption of capital to fund research and development activities.
The consistent decline in equity highlights the company's inability to generate internal capital, forcing a reliance on external financing that appears to be eroding shareholder value. Investors should monitor whether this trajectory stabilizes or if further capital raises will be required to prevent a total depletion of the equity base.
According to the company's balance sheet data, total debt has surged from $160,000 in 2022Q3 to $22.1 million in 2024Q2, resulting in a D/E ratio of 7.90 that suggests a high degree of financial risk and limited capacity for additional non-dilutive borrowing.
The rapid accumulation of debt relative to a shrinking equity base indicates that the company is increasingly reliant on leverage to sustain its operations. This high leverage profile may limit future strategic flexibility and suggests that the company's cash flow durability remains highly questionable in the current interest rate environment.
Based on the most recent quarterly figures, Moolec's cash position has dwindled to $1.9 million, a stark reduction from the $10.4 million reported in 2022Q2, which leaves the company with a minimal buffer against operational shocks or unexpected delays in its biotech commercialization pipeline.
While the current ratio of 1.48 might appear superficially adequate, the absolute cash level is alarmingly low given the company's historical burn rate. This liquidity position warrants close investigation, as it suggests the firm may face imminent pressure to secure additional funding to maintain its ongoing research operations.
As indicated by the provided financial statements, the company's asset base is heavily weighted toward liabilities, with total assets of $31.4 million barely covering the $28.6 million in total liabilities, leaving little room for error in the valuation of its intangible assets or inventory.
The reliance on a thin asset cushion suggests that any impairment in the value of its biotech IP or agricultural inventory could quickly push the company into a technical insolvency position. Investors should be wary of the potential for non-cash write-downs that could further destabilize the already fragile balance sheet.
Quick answers to the most common questions about buying MLEC stock.
As of 2024, Moolec Science S.A. (MLEC) had total assets of $204.7M including $31.2M in current assets.
Moolec Science S.A. (MLEC) carries total debt of $246.9M, offset by $9.0M in cash and short-term investments. Comparing total debt to cash helps evaluate the company's debt burden and net leverage.
Moolec Science S.A. (MLEC) has total shareholders' equity (book value) of $-66.0M ($-192.34 book value per share). Book value represents the net worth of the company belonging to common stock holders.
Moolec Science S.A. (MLEC) reported a current ratio of 0.13x. A current ratio above 1.0x indicates that the company has more current assets than current liabilities, suggesting sufficient short-term liquidity.